undamentalytics Newsletter
Sign in

Coherus Oncology, Inc. income statement

In fiscal 2025, Coherus Oncology, Inc. reported revenue of $42.2m, up 59.8% on the year before, operating income of −$181m (a -429.5% margin) and net income of $168m, or $1.43 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue23313019020356476327211257264251
Cost of revenue———————1738587015991416
Gross profit———————33943826914198182835
Research and development3531782132541621109414336319910992109101
Selling, general and administrative————52719413713917019819212510193
General and administrative671836———————————
Operating income−39−36−65−219−116−232−204108156−264−257−203−200−181−159
Interest expense25408101018212332411199
Income before tax—————−238−20993136−287−292−238−215−183−161
Income tax——000003300−000—
Net income−33−54−87−223−127−238−20990132−287−292−23829168−132
Diluted EPS−$15.85−$16.10−$10.64−$6.01−$3.04−$4.48−$3.22$1.23$1.62−$3.81−$3.76−$2.53$0.25$1.43−$1.00
Diluted shares (average)2m3m8m37m42m53m65m73m83m75m78m94m115m117m132m
EBITDA−38−36−64−217−113−229−201111159−260−253−200−198−180−156

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CHRS vs OCULCHRS vs GOSSCHRS vs SIGA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Coherus Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Coherus Oncology, Inc.